Short answer
MEN1 genetic testing looks for inherited variants in the MEN1 gene when multiple endocrine neoplasia type 1 is suspected. The classic pattern involves parathyroid tumors or hyperparathyroidism, pituitary tumors, and pancreatic or duodenal neuroendocrine tumors, but family history, younger age, multigland parathyroid disease, gastrinoma, or multiple pancreatic NETs can also shape the testing question.
When MEN1 testing usually fits
| Situation | Testing question | Why it matters |
|---|---|---|
| Two or more MEN1-associated tumors | Does the clinical pattern fit MEN1 or a related syndrome? | Testing can change surveillance and family testing. |
| Known family MEN1 variant | Should relatives have targeted testing? | Targeted testing can clarify who needs lifelong screening. |
| Negative or uncertain result | Did testing include deletion/duplication analysis, and is the phenotype still suspicious? | A negative test may not fully settle a strong clinical pattern. |
| Early hyperparathyroidism or a gastrinoma | Could MEN1 explain the endocrine pattern before more tumors appear? | Earlier diagnosis can change the surveillance plan. |
What the result can change
A pathogenic MEN1 result can affect endocrine surveillance, imaging strategy, family communication, reproductive planning, and whether relatives are offered targeted testing. MEN1 is not just about one hormone or one gland; it is about anticipating the full tumor pattern and screening before symptoms become the main clue.
A variant of uncertain significance should not be treated like a confirmed diagnosis without genetics input.
Why negative or tumor-only results do not always settle the question
A negative result does not always rule out MEN1 if the clinical pattern is strong or if the assay did not include deletion and duplication analysis. Tumor-only findings also need careful germline confirmation before family members are managed as if they are at risk.
That matters because MEN1 surveillance often starts early and can be lifelong, so the difference between tumor biology and inherited risk changes the whole family plan.
Questions to ask
- Was this germline testing, tumor-only testing, or raw consumer data?
- Does the assay include both sequencing and deletion/duplication analysis?
- Which tumors, hormone labs, or imaging findings raised the MEN1 question?
- Could a related endocrine syndrome or phenocopy fit better?
- Would genetic counseling help relatives understand targeted testing and surveillance timing?
What the result still cannot prove
A MEN1 result can support inherited risk, but it does not tell you exactly when tumors will appear, how severe the course will be, or whether every relative will have the same pattern. Counseling and family history still matter.
FAQ
What does MEN1 genetic testing look for?
It looks for inherited variants in the MEN1 gene that can explain a pattern of parathyroid, pituitary, and pancreatic or duodenal endocrine tumors.
Does a negative result rule out MEN1?
No. A negative result lowers the chance, but it does not fully rule it out if the phenotype is strong or if deletion/duplication analysis was missing.
Why does deletion/duplication analysis matter?
Some clinically important MEN1 changes are not simple sequence variants, so a sequence-only test can miss them.
Can MEN1 be diagnosed without genetic testing?
Yes. NIDDK says MEN1 can be diagnosed clinically when the tumor pattern or a known family diagnosis is present, but genetic testing helps clarify family risk.
When should relatives be tested?
If a pathogenic familial variant is found, first-degree relatives are usually the first people offered targeted testing and surveillance planning.
Why do children come up in MEN1 counseling?
NIDDK notes that targeted testing for a known familial variant may be appropriate starting around age 5, because MEN1 can appear in childhood in rare cases.
Related guides: hereditary cancer genetic testing, VHL genetic testing, RET MEN2 genetic testing, and genetic counselor guide.